litlas
ログインアカウント作成

Gregory A. Otterson

1995–2025 年に発表

106
論文数
27,404
被引用数
79
h 指数
104
i10 指数

被引用数

Gregory A. Otterson の年別被引用数1983 年: 被引用 1 件1990 年: 被引用 1 件1993 年: 被引用 1 件1994 年: 被引用 1 件1995 年: 被引用 14 件1996 年: 被引用 26 件1997 年: 被引用 31 件1998 年: 被引用 49 件1999 年: 被引用 66 件2000 年: 被引用 37 件2001 年: 被引用 47 件2002 年: 被引用 52 件2003 年: 被引用 54 件2004 年: 被引用 70 件2005 年: 被引用 67 件2006 年: 被引用 66 件2007 年: 被引用 71 件2008 年: 被引用 76 件2009 年: 被引用 75 件2010 年: 被引用 67 件2011 年: 被引用 93 件2012 年: 被引用 103 件2013 年: 被引用 109 件2014 年: 被引用 120 件2015 年: 被引用 165 件2016 年: 被引用 223 件2017 年: 被引用 263 件2018 年: 被引用 287 件2019 年: 被引用 1,214 件2020 年: 被引用 1,431 件2021 年: 被引用 1,411 件2022 年: 被引用 1,054 件2023 年: 被引用 760 件2024 年: 被引用 1,224 件2025 年: 被引用 427 件2026 年: 被引用 12 件1984〜1989 年は被引用が無いため表示していません1991〜1992 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,471 件、この内訳の 24.9%中国: 引用元論文 2,603 件、この内訳の 18.7%イタリア: 引用元論文 759 件、この内訳の 5.4%ドイツ: 引用元論文 603 件、この内訳の 4.3%イギリス: 引用元論文 598 件、この内訳の 4.3%フランス: 引用元論文 574 件、この内訳の 4.1%日本: 引用元論文 573 件、この内訳の 4.1%スペイン: 引用元論文 453 件、この内訳の 3.2%カナダ: 引用元論文 414 件、この内訳の 3%韓国: 引用元論文 345 件、この内訳の 2.5%オーストラリア: 引用元論文 324 件、この内訳の 2.3%スイス: 引用元論文 307 件、この内訳の 2.2%
0%24.9%その他 21%

機関

分野

  • Medicine69.3%
  • Biochemistry, Genetics and Molecular Biology24.4%
  • Immunology and Microbiology2.7%
  • Neuroscience0.8%
  • Engineering0.6%
  • Computer Science0.5%
  • その他1.7%

トピック

  • Cancer Immunotherapy and Biomarkers11.8%
  • Lung Cancer Treatments and Mutations10.1%
  • Lung Cancer Diagnosis and Treatment5.7%
  • Lung Cancer Research Studies5.5%
  • Cancer Genomics and Diagnostics4.1%
  • Immunotherapy and Immune Responses2.3%
  • その他60.5%

共著者

全論文

検索で開く
  1. Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

    著者: David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Débora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Malcolm M. DeCamp, Thomas J. Dilling, Jonathan E. Dowell, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Jose M. Pacheco, Sandip Pravin Patel, Gregory J. Riely, Jonathan W. Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda L. Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2022 被引用: 1,419

  2. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

    著者: Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański, Jong Seok Lee, Gregory A. Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak A. Burgers, Pamela Salman, Hossein Borghaei, Suresh S. Ramalingam, Julie R. Brahmer, Martin Reck, Kenneth J. O’Byrne, William J. Geese, George Green, Chang Han, Joseph D. Szustakowski, Prabhu Bhagavatheeswaran, Diane Healey, Yali Fu, Faith E. Nathan, Luis Paz‐Ares - New England Journal of Medicine 2018 被引用: 3,137

  3. NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023

    著者: David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Débora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm M. DeCamp, Thomas J. Dilling, Jonathan E. Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip Pravin Patel, Tejas Patil, Patricio M. Polanco, Gregory J. Riely, Jonathan W. Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda L. Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2023 被引用: 483

  4. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

    著者: David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Débora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Jonathan E. Dowell, Scott Gettinger, Matthew A. Gubens, Aparna Hegde, Mark Hennon, Rudy P. Lackner, Michael Lanuti, Ticiana Leal, Jules Lin, Billy W. Loo, Christine M. Lovly, Renato Martins, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip Pravin Patel, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda L. Tam, Jane Yanagawa, Stephen C. Yang, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2021 被引用: 1,006

  5. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer

    著者: Bairavi Shankar, Jiajia Zhang, Abdul Rafeh Naqash, Patrick M. Forde, Josephine Feliciano, Kristen A. Marrone, David S. Ettinger, Christine L. Hann, Julie R. Brahmer, Biagio Ricciuti, Dwight H. Owen, Yukihiro Toi, Paul R. Walker, Gregory A. Otterson, Sandip H. Patel, Shunichi Sugawara, Jarushka Naidoo - JAMA Oncology 2020 被引用: 489

  6. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    著者: Luis Paz‐Ares, Suresh S. Ramalingam, Tudor–Eliade Ciuleanu, Jong-Seok Lee, László Urbán, Reyes Bernabe Caro, Keunchil Park, Hiroshi Sakai, Yuichiro Ohe, Makoto Nishio, Clarisse Audigier-Valette, Jacobus A. Burgers, Adam Płużański, Randeep Sangha, Carlos Gallardo, Masayuki Takeda, Helena Linardou, Lorena Lupinacci, Ki Hyeong Lee, Claudia Caserta, Mariano Provencio, Enric Carcereny, Gregory A. Otterson, Michael Schenker, Bogdan Żurawski, Aurelia Alexandru, A. Vergnenègre, Judith Raimbourg, Kynan Feeney, Sang‐We Kim, Hossein Borghaei, Kenneth J. O’Byrne, Matthew D. Hellmann, Arteid Memaj, Faith E. Nathan, Judith Bushong, Phuong Tran, Julie R. Brahmer, Martin Reck - Journal of Thoracic Oncology 2021 被引用: 322

  7. First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

    著者: Neal Ready, Matthew D. Hellmann, Mark M. Awad, Gregory A. Otterson, Martin Gutierrez, Justin F. Gainor, Hossein Borghaei, Jacques Jolivet, Leora Horn, Mihaela Mates, Julie R. Brahmer, Ian Rabinowitz, Pavan S. Reddy, Jason Chesney, James Michael Orcutt, David R. Spigel, Martin Reck, Kenneth J. O’Byrne, Luis Paz‐Ares, Wenhua Hu, Kim E. Zerba, Xuemei Li, Brian Lestini, William J. Geese, Joseph D. Szustakowski, George Green, Chang Han, Suresh S. Ramalingam - Journal of Clinical Oncology 2019 被引用: 596

  8. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer

    著者: Gregory J. Riely, Egbert F. Smit, Myung‐Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne S. Tsao, Melissa L. Johnson, Francesco Gelsomino, Raymond M. Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo‐Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith D. Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E. Johnson - Journal of Clinical Oncology 2023 被引用: 114

  9. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

    著者: Alexander Drilon, Salvatore Siena, Rafał Dziadziuszko, Fabrice Barlési, Matthew Krebs, Alice T. Shaw, Filippo de Braud, Christian Rolfo, Myung‐Ju Ahn, Jürgen Wolf, Takashi Seto, Byoung Chul Cho, Manish R. Patel, Chao‐Hua Chiu, Thomas John, Kōichi Goto, Christos S. Karapetis, Hendrick-Tobias Arkenau, Sang-We Kim, Yuichiro Ohe, Yu Li, Young Kwang Chae, Christine H. Chung, Gregory A. Otterson, Haruyasu Murakami, Chia‐Chi Lin, Daniel Shao-Weng Tan, Hans Prenen, Todd Riehl, Edna Chow‐Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R. Wilson, Robert C. Doebele - The Lancet Oncology 2019 被引用: 537

  10. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

    著者: Alexander Drilon, Jeffrey W. Clark, Jared Weiss, Sai‐Hong Ignatius Ou, D. Ross Camidge, Benjamin Solomon, Gregory A. Otterson, Liza C. Villaruz, Gregory J. Riely, Rebecca S. Heist, Mark M. Awad, Geoffrey I. Shapiro, Miyako Satouchi, Toyoaki Hida, Hidetoshi Hayashi, Danielle Murphy, Sherry Wang, Sherry Li, Tiziana Usari, Keith D. Wilner, Paul K. Paik - Nature Medicine 2020 被引用: 393

  11. Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

    著者: David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Lucian R. Chirieac, Thomas A. D’Amico, Malcolm M. DeCamp, Thomas J. Dilling, M.C. Dobelbower, Robert C. Doebele, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Ticiana Leal, Leah J. Leisch, Rogerio Lilenbaum, Jules Lin, Billy W. Loo, Renato Martins, Gregory A. Otterson, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Steven Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2017 被引用: 1,325

  12. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

    著者: Michael Boyer, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu, Keunchil Park, Dae Ho Lee, İrfan Çiçin, Perran Fulden Yumuk, Francesco Orlandi, Ticiana Leal, Olivier Molinier, Nopadol Soparattanapaisarn, Adrian Langleben, Raffaele Califano, Balazs Medgyasszay, Te‐Chun Hsia, Gregory A. Otterson, Lu Xu, Bilal Piperdi, Ayman Samkari, Martin Reck, for the KEYNOTE-598 Investigators - Journal of Clinical Oncology 2021 被引用: 253

  13. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

    著者: Naiyer A. Rizvi, Julien Mazières, David Planchard, Thomas E. Stinchcombe, Grace K. Dy, Scott Antonia, Leora Horn, H. Léna, Elisa Minenza, B. Mennecier, Gregory A. Otterson, Luis T. Campos, David R. Gandara, Benjamin Levy, Suresh Nair, Gérard Zalcman, Jürgen Wolf, Pierre‐Jean Souquet, Editta Baldini, Federico Cappuzzo, C. Chouaïd, Afshin Dowlati, Rachel E. Sanborn, Ariel López-Chávez, Christian Grohé, Rudolf M. Huber, Christopher Harbison, Christine Baudelet, Brian Lestini, Suresh S. Ramalingam - The Lancet Oncology 2015 被引用: 1,429

  14. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

    著者: Jacob J. Chabon, Andrew D. Simmons, Alexander F. Lovejoy, Mohammad Shahrokh Esfahani, Aaron M. Newman, Henry J. Haringsma, David M. Kurtz, Henning Stehr, Florian Scherer, Chris Karlovich, Thomas C. Harding, Kathleen A. Durkin, Gregory A. Otterson, W. Thomas Purcell, D. Ross Camidge, Jonathan W. Goldman, Lecia V. Sequist, Zofia Piotrowska, Heather A. Wakelee, Joel W. Neal, Ash A. Alizadeh, Maximilian Diehn - Nature Communications 2016 被引用: 659

  15. Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

    著者: Alexander Drilon, Chao‐Hua Chiu, Yun Fan, Byoung Chul Cho, Shun Lü, Myung‐Ju Ahn, Matthew Krebs, Stephen V. Liu, Thomas John, Gregory A. Otterson, Daniel S.W. Tan, Tejas Patil, Rafał Dziadziuszko, Erminia Massarelli, Takashi Seto, Robert C. Doebele, Bethany Pitcher, Nino Kurtsikidze, Sebastian Heinzmann, Salvatore Siena - JTO Clinical and Research Reports 2022 被引用: 113

  16. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020

    著者: David S. Ettinger, Douglas E. Wood, Charu Aggarwal, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Débora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, M.C. Dobelbower, Scott Gettinger, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana Leal, Jules Lin, Billy W. Loo, Renato Martins, Gregory A. Otterson, Sandip Pravin Patel, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina M. Gregory, OCN, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2019 被引用: 1,005

  17. Advances in epigenetic therapeutics with focus on solid tumors

    著者: Ning Jin, Tiffany L. George, Gregory A. Otterson, Claire F. Verschraegen, Haitao Wen, David P. Carbone, James G. Herman, Erin M. Bertino, Kai He - Clinical Epigenetics 2021 被引用: 125

  18. Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic Model

    著者: Nathan A. Pennell, Alex Mutebi, Zheng‐Yi Zhou, Marie Louise Ricculli, Wenxi Tang, Helen Wang, Annie Guérin, Tom Arnhart, Anand A. Dalal, Medha Sasané, Kevin Y. Wu, Kenneth W. Culver, Gregory A. Otterson - JCO Precision Oncology 2019 被引用: 222

  19. Crizotinib in Patients With MET-Amplified NSCLC

    著者: D. Ross Camidge, Gregory A. Otterson, Jeffrey W. Clark, Sai‐Hong Ignatius Ou, Jared Weiss, Steven Ades, Geoffrey I. Shapiro, Mark A. Socinski, Danielle Murphy, Umberto Conte, Yiyun Tang, Sherry Wang, Keith D. Wilner, Liza C. Villaruz - Journal of Thoracic Oncology 2021 被引用: 168

  20. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

    著者: Scott Antonia, Hossein Borghaei, Suresh S. Ramalingam, Leora Horn, Javier de Castro, Adam Płużański, Marco Angelo Burgio, Marina Chiara Garassino, Laura Q.M. Chow, Scott Gettinger, Lucio Crinò, David Planchard, Charles Butts, Alexander Drilon, Joanna Wójcik-Tomaszewska, Gregory A. Otterson, Shruti Agrawal, Ang Li, John R. Penrod, Julie R. Brahmer - The Lancet Oncology 2019 被引用: 365

  21. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016

    著者: David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, M.C. Dobelbower, Ramaswamy Govindan, Mark Hennon, Leora Horn, Thierry Jahan, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Rogério Lilenbaum, Jules Lin, Billy W. Loo, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M.W. Pisters, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Neelesh Sharma, James Stevenson, Steven Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2016 被引用: 738

  22. Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non–Small-cell Lung Cancer

    著者: Dwight H. Owen, Lai Wei, Erin M. Bertino, Thomas Edd, Miguel A. Villalona‐Calero, Kai He, Peter G. Shields, David P. Carbone, Gregory A. Otterson - Clinical Lung Cancer 2018 被引用: 147

  23. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

    著者: Hamzah Abu‐Sbeih, Faisal S. Ali, Abdul Rafeh Naqash, Dwight H. Owen, Sandipkumar Patel, Gregory A. Otterson, Kari Kendra, Biagio Ricciuti, Rita Chiari, Andrea De Giglio, Joseph Sleiman, Pauline Funchain, Wills Beatriz, Jiajia Zhang, Jarushka Naidoo, Jessica Philpott, Jianjun Gao, Sumit K. Subudhi, Yinghong Wang - Journal of Clinical Oncology 2019 被引用: 197

  24. Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival

    著者: Abdul Miah, Gabriel Tinoco, Songzhu Zhao, Lai Wei, Andrew Johns, Sandip Pravin Patel, Mingjia Li, Madison Grogan, Gabrielle Lopez, Marium Husain, Rebecca Hoyd, Khalid Mumtaz, Alexa Meara, Erin M. Bertino, Kari Kendra, Daniel Spakowicz, Gregory A. Otterson, Carolyn J. Presley, Dwight H. Owen - Journal of Cancer Research and Clinical Oncology 2022 被引用: 40